Immuneering Corporation (NASDAQ: IMRX) announced that the first patient has been dosed in its MAPKeeper 301 phase 3 clinical trial ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE